One of the biggest mistakes patients make is believing that a higher dose automatically means better results
Patients must understand the risks inherent in GLP-1 therapy, including the effects on anesthesia, the potential for muscle mass loss, the likelihood of weight regain upon discontinuation, and the importance of honest self-reporting
Particular focus was on IcoSema, a new drug by Novo Nordisk that combines once-weekly insulin icodec (approved in Europe and other countries, but not yet the U.S.) and semaglutide, a GLP-1 agonist
Any storage deviation must be documented and reported to the trial team, as it may constitute a protocol deviation requiring formal reporting
Online Metabolic & Molecular Bases of Inherited Disease, The McGraw-Hill Companies, New York 2001:3897-933 6
Why the Blend Combines Tesamorelin and Ipamorelin The two compounds hit growth hormone release through different receptors